APA aipamena

Soverini, S., Rosti, G., Iacobucci, I., Baccarani, M., & Martinelli, G. (2011). Choosing the Best Second-Line Tyrosine Kinase Inhibitor in Imatinib-Resistant Chronic Myeloid Leukemia Patients Harboring Bcr-Abl Kinase Domain Mutations: How Reliable Is the IC(50)? AlphaMed Press.

Chicago Style aipamena

Soverini, Simona, Gianantonio Rosti, Ilaria Iacobucci, Michele Baccarani, and Giovanni Martinelli. Choosing the Best Second-Line Tyrosine Kinase Inhibitor in Imatinib-Resistant Chronic Myeloid Leukemia Patients Harboring Bcr-Abl Kinase Domain Mutations: How Reliable Is the IC(50)? AlphaMed Press, 2011.

MLA aipamena

Soverini, Simona, et al. Choosing the Best Second-Line Tyrosine Kinase Inhibitor in Imatinib-Resistant Chronic Myeloid Leukemia Patients Harboring Bcr-Abl Kinase Domain Mutations: How Reliable Is the IC(50)? AlphaMed Press, 2011.